Upstream Bio, Inc. (UPB) stock
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.08−0.02 (-0.95%)
Close on Nov 18, 2026Market cap $113.92MP/E –Yield –
Upstream Bio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Upstream Bio's revenue for the twelve months ending Sep 30, 2026 was $2.87M, up 2.5% year over year. For fiscal 2025 it was $2.85M, up 20.4% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.85M | +20.4% |
| FY2024 | Dec 31, 2024 | $2.37M | -0.4% |
| FY2023 | Dec 31, 2023 | $2.38M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $395.00K | -42.2% |
| Q2 FY2026 | Jun 30, 2026 | $773.00K | -17.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.03M | +82.7% |
| Q4 FY2025 | Dec 31, 2025 | $668.00K | +9.0% |
| Q3 FY2025 | Sep 30, 2025 | $683.00K | +12.5% |
| Q2 FY2025 | Jun 30, 2025 | $937.00K | +83.7% |
| Q1 FY2025 | Mar 31, 2025 | $566.00K | -11.6% |
| Q4 FY2024 | Dec 31, 2024 | $613.00K | +36.2% |
| Q3 FY2024 | Sep 30, 2024 | $607.00K | -2.3% |
| Q2 FY2024 | Jun 30, 2024 | $510.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $640.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $450.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $621.00K | – |
See a number that looks wrong?